NCT01723111
Completed
Not Applicable
A Prospective, Multicenter, Observational Study to Evaluate the Impact of Peritoneal Dialysis Compared With Hemodialysis on Iron Metabolism and Hepcidin
ConditionsEnd-stage Renal Disease
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- End-stage Renal Disease
- Sponsor
- Kyungpook National University Hospital
- Enrollment
- 120
- Locations
- 4
- Primary Endpoint
- ESA (Erythrocyte stimulating agents) dose
- Status
- Completed
- Last Updated
- 8 years ago
Overview
Brief Summary
- Dialysis modality may influence the oxidative stress and proinflammatory cytokines in ESRD patients.
- Dialysis modality may affect hepcidin
- Dialysis modality may influence iron and ESA requirements.
Detailed Description
It has been considered that PD patients tended to be less anemic and require lower ESA dose than HD patients. In addition, it was also known that the level of oxidative stress and inflammatory cytokines tended to be lower in PD patients than HD patients. And hepcidin synthesis is markedly increased during inflammation. Altogether, Lower ESA requirement in PD patients may be associated with lower hepcidin level due to lower inflammatory state compared with HD patients.
Investigators
Yong-Lim Kim
MD, PhD
Kyungpook National University Hospital
Eligibility Criteria
Inclusion Criteria
- •Written informed consent
- •Age 18 years or older
- •Dialysis treatment was expected over 3 months
- •In HD patients, regular hemodialysis 4 h a session more than two times a week
- •In PD patients, over 2 exchange with more than 1.5 L solution
Exclusion Criteria
- •Poorly controlled hypertension, i.e. sitting blood pressure exceeding 180/110 despite medication requiring hospitalization or interruption of ESA treatment
- •Significant acute or chronic bleeding such as overt gastrointestinal bleeding within the previous 3 months
- •Active malignant disease (except non-melanoma skin cancer and patients with malignant disease who have been disease-free for at least the 5 previous years are eligible)
- •Acute infection
- •Hemolysis
- •Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
- •Megaloblastic anemia
- •Platelet count \>500 x 109/L or \<100 x 109/L
- •Pure red call aplasia
- •Epileptic seizure during previous 3 months
Outcomes
Primary Outcomes
ESA (Erythrocyte stimulating agents) dose
Time Frame: six months
We will compare ESA dose between PD patients and HD patients
Secondary Outcomes
- Hepcidin level(six months)
- hs-CRP(six months)
- IL-6(six months)
- Total antioxidant capacity(six months)
- IV iron treatment (% of patients)(six months)
- Transfusion rate(six months)
- Myeloperoxidase(six months)
- TNF-a(six months)
Study Sites (4)
Loading locations...
Similar Trials
Completed
Phase 4
Effect of Paricalcitol on Markers of Inflammation in Hemodialysis PatientsKidney FailureNCT00294866Fresenius Medical Care North America64
Completed
Phase 4
Comparison of the Impact of Dialysis Treatment Type on Patient SurvivalEnd Stage Renal DiseaseNCT00510549Baxter Healthcare Corporation50
Completed
Phase 2
Provision of Antioxidant Therapy in Hemodialysis (PATH) StudyEnd-stage Renal DiseaseNCT00237718Vanderbilt University385
Completed
Not Applicable
Improvement of EPO-resistance in Hemodialysis Patients With Chronic Inflammation by High Cut-off HemodialysisEnd-Stage Renal Disease (ESRD)NCT01526798Vantive Health LLC24
Terminated
Phase 2
A Safety Study of Pentoxifylline for the Treatment of AnemiaEnd Stage Renal DiseaseNCT01102218Fresenius Medical Care North America48